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Abstract: Some epidemiological evidence shows a link between abnormality of lipid profiles and variations in serum calcium. 
However, it is unknown whether this association resulted from confounding factors. The present study was designed to investigate the 
relationship between serum lipids and calcium. Serum calcium was corrected for albumin. Major confounding factors including age, 
gender, medications, menopause, parathyroid hormone (PTH) and 25-OH-vitamin D status were controlled in analyses. A total of 1907 
adult subjects from the province of Newfoundland and Labrador (NL), Canada participated in the study. Significant positive correlations 
were detected between serum total cholesterol and high density lipoprotein-cholesterol (HDL-c) with variations of serum Ca++ in both 
genders (p  0.05–0.0001). Significant positive correlations were additionally detected between triglycerides (TG) and low density 
lipoprotein-cholesterol (LDL-c) with Ca++ in women only (p  0.0001) in partial correlation analyses. Similar significant results were 
detected in both females and males not taking any medication. Analyses were performed based on menopausal status as well. Significant 
correlations were seen in both pre- and post-menopausal women but higher correlation coefficients were observed in pre-menopausal 
women as compared to post-menopausal women. Subjects with low calcium levels had the lowest concentration of total cholesterol, TG, 
HDL-c and LDL-c, while subjects with high calcium levels had the highest concentration of all four markers in women. The significant 
associations between cholesterol, TG and LDL-c and serum Ca++ remained after calcium was adjusted for 25-OH-vitamin D and PTH. 
Our results indicate that the abnormality of serum lipid profiles are significantly correlated with altered serum Ca++ levels independent 
of age, obesity status, medication, phosphorus, magnesium, 25-OH-vitamin D and PTH.
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Introduction
An abnormal lipid profile or dyslipidemia is defined 
by an elevation of plasma cholesterol, LDL-cholesterol 
(LDL-c) and/or TGs or a low HDL-cholesterol 
(HDL-c) level. Primary dyslipidemia can be found 
in several monogenic disorders that lead to different 
types of dyslipidemias.1–3 In many cases the etiology 
is polygenic. Primary dylipidemia affect plasma 
lipoprotein levels by overproduction of lipoproteins 
and/or decreased clearance.1–3 Secondary dyslipidemia 
can be caused by many medical conditions which are 
associated with mild or even severe dyslipidemia 
even in the absence of an underlying genetic disorder. 
These conditions include, but are not limited to, diabetes 
mellitus (DM), obesity, alcohol overuse, chronic renal 
insufficiency and/or failure, hypothyroidism, liver 
diseases, rheumatoid arthritis, pregnancy and the 
use of drugs such as thiazides, β-blockers, retinoids 
and sex hormones.4–9 Cholesterol and other lipids 
can come from the diet as well as from endogenous 
synthesis. Triglycerides are synthesized from fatty 
acids or from glucose.
It has been observed that a cluster of diseases and 
syndromes including hypertension, insulin resistance, 
type 2 DM and atherosclerosis clinically often coexist 
or overlap.10–14 Lind et al found that blood pressure 
and serum glucose and cholesterol concentrations 
were all positively related to each other in a large adult 
population.15 The specific biochemical pathways that 
are dysregulated in dyslipidemia and the molecular 
mechanisms that lead to the dysfunction in the 
general population, except for those caused by clear 
genetic and secondary conditions, remain unclear. 
Calcium is a versatile intracellular messenger that 
is involved throughout the life cycle of an organism 
to control diverse biological processes.16 It has been 
suggested that diabetes and cardiovascular disease 
are linked by a common defect of divalent cation 
metabolism, including calcium.17 Insulin resistance, 
a state in which increased concentrations of insulin 
are required to produce a given biological response, 
has been the focus of attention for a common link 
between several clinical disorders with dyslipidemia 
as one group of the clinical manifestation.18–20 Our 
previous study has shown that altered serum calcium 
homeostasis is at least partially responsible for insulin 
resistance in the general population.21 Data from a 
Swedish group supported our findings.22 These data 
strengthen the theory that calcium might be the 
central link between dyslipidemia, insulin resistance 
in hypertension, diabetes and atherosclerosis. Some 
preliminary association at the population level has 
been reported in previous studies, including the 
Framingham Heart Study,23 where relationships 
between calcium and general biological markers,24 
and metabolic syndrome15 were found. However, 
the general association was not further discussed 
and left many questions unanswered because of the 
complicated nature of lipid abnormality and serum 
calcium variation. Variations of lipids and serum 
calcium can be potentially influenced by many factors 
including age, gender, obesity status, medication use, 
physical activity level and other diseases such as 
diabetes.4–9
The present study was designed to further investigate 
the relationship between lipids and serum calcium 
by controlling for major confounding factors including 
medications, disease status, menopause, parathyroid 
hormone (PTH) and 25-OH-vitamin D status in 
addition to the common confounding factors of  age and 
gender, in a large adult population from the Canadian 
province of  Newfoundland and Labrador (NL).
Research Design and Methods
research volunteers
A total of 1907 adults were recruited from an ongoing 
large-scale nutritional genetics study of human 
complex diseases called the CODING (Complex 
Diseases in the Newfoundland population: Environment 
and Genetics) study.25 The CODING study is being 
performed in the province of NL, Canada. The 
volunteers were recruited for the study of genetic and 
lifestyle factors including genetic variations, nutrition, 
physical activity, and the interactions of genetics and 
lifestyle in the development of obesity, diabetes and 
osteoporosis. This is a study with a cross-sectional 
design and is being developed into a longitudinal 
study with the funding support by the Canadian 
Institute of Health Research (CIHR). Information 
regarding study design, criteria for participation, 
and body composition measurements can be found 
in our previously published papers.21,25,26 Potential 
participants gave written consent and completed a 
screening questionnaire to provide general personal 
information and general lifestyle characteristics. 
Eligible participants were 19 years of age and older, 
Abnormal lipid profile and serum Ca++
Clinical Medicine: Endocrinology and Diabetes 2009:2 17
born in NL in a family who lived in NL for at least 
three generations, and healthy without serious 
metabolic, cardiovascular or endocrine diseases. Body 
mass index (BMI) was calculated as body weight 
(kg) divided by height (m) squared. Subjects who 
self-reported having DM or who had fasting glucose 
levels 7.0 mmol/L were designated as having DM. 
The study received ethics approval from the Human 
Investigations Committee of the Faculty of Medicine 
at Memorial University of Newfoundland.
Biochemical measurements
Blood samples were obtained from all subjects after 
they had fasted for 12 h. Serum concentrations of total 
calcium, phosphorus, magnesium, triglycerides, total 
cholesterol, and HDL-c were measured. Additionally, 
glucose and albumin were measured using Synchron 
reagents performed on an LX20 clinical chemistry 
analyzer (Beckman Coulter, Fullerton, CA). Serum 
total calcium concentration was corrected by 
serum albumin [calcium + 0.1 × (40—albumin)/6].21 
LDL-c was calculated by using the following 
formula: cholesterol—HDL-c—(triglycerides/2.2). 
The LDL-c calculation is reliable in the absence of 
severe hyperlipidemia. Serum parathyroid hormone 
(PTH) and insulin were measured on an Immulite 
immunoassay analyzer using the IMMULITE 1000 
Intact PTH kit (Diagnostic Products Corporation, Los 
Angeles, CA). 25-OH-vitamin D was measured using 
a 25-Hydroxyvitamin D 125 I RIA Kit (DiaSorin, 
Stillwater, MN). Homeostasis model assessment was 
used to estimate insulin resistance and β-cell function.27
Measurement of body composition
Total body fat [percentage body fat (%BF)] and 
trunk fat percentage were measured by using dual-
energy X-ray absorptiometry (Lunar Prodigy; GE 
Medical Systems, Madison, WI). Measurements were 
performed on subjects after the removal of all metal 
accessories and while the subjects were in a supine 
position, as previously described.28 ENCORE 2002 
software version 6.70 was used for analysis.
statistical analysis
Data are presented as means ± SD. The analyses consist 
of the following parts. First, partial correlation analyses 
were performed between the levels of serum calcium 
and the levels of total cholesterol, TG, HDL-c and 
LDL-c within sex after controlling for the confounding 
variables. Second, partial correlations were repeated 
according to medication use and menopausal status 
(pre- and post-menopausal women), i.e. within group 
with or without medication use, and within group of 
pre- or post-menopausal women. Third, in one-way 
ANOVA analyses, adjustments for the effects of 
covariates on serum calcium, cholesterol, TG, HDL-c 
and LDL-c were carried out using a linear regression 
procedure. The covariates for serum calcium and 
lipids were age, phosphorus, and magnesium; percent 
trunk fat was also included as a covariate in the 
analyses for serum lipids. The results from one-way 
ANOVA were corrected by the TUKEY method. 
Fourth, to account for the influences of vitamin D and 
PTH, subjects from the “medication-free” group were 
ranked according to serum calcium concentration; 
100 women (top 50 and bottom 50) were selected, 
and the serum concentrations of 25-OH vitamin D 
and PTH were measured. Total serum calcium levels 
were adjusted for the concentrations of 25-OH 
vitamin D and PTH using a linear regression model 
before analysis. The levels of total cholesterol, TG, 
HDL-c and LDL-c were then compared between the 
low and high calcium groups using a student t test. 
All analyses were performed using the SPSS software 
for Windows, version 15.0.
Confounding factors
In addition to serum calcium, evidences from both 
human and animal experiments show that magnesium 
may exert influence on lipid metabolism.29–32 The 
use of medications is probably the biggest factor 
that modifies the lipids either primarily by treating 
dyslipidemia or secondarily through other medical 
processes such as hormone replacement therapy in 
women. Obesity status is the most prominent risk 
factor contributing to metabolic syndrome and lipid 
abnormalities, especially central obesity.4,33 Trunk 
fat percentage was found to be more significantly 
associated with lipids in our primary analysis using 
Pearson correlation than total body fat percentage. 
Therefore, we chose trunk fat percentage as the 
covariate representing body composition.
Results
The physical characteristics and biochemical 
measurements of the adult population studied are 
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shown in Table 1. There are significant differences 
in all physical characteristics and biochemical 
markers except for total serum calcium concentration 
corrected for serum albumin (serum Ca++-C), 
Mg++ and LDL-c, in the comparison between women 
and men.
The results of the partial correlations between 
serum Ca++-C and lipid markers based on gender 
are shown in Table 2. Significant positive correlations 
of  serum total cholesterol, TG, HDL-c and LDL-c with 
serum Ca++-C were found in women (r = 0.26, r = 0.16, 
r = 0.11 and r = 0.19, respectively; p  0.0001 for all 
variables). Significant correlations between serum 
Ca++-C and serum total cholesterol, HDL-c and 
LDL-c were also observed for men (r = 0.13, r = 0.12 
and r = 0.10, respectively; p = 0.05 to 0.009).
Women and men not taking any medication were 
analyzed using partial correlation, controlling for age, 
trunk fat, phosphorus and magnesium (Table 3). The 
significant positive correlations remained between 
serum Ca++-C and lipids in women, but the significant 
HDL-c correlation was lost in men.
Women were further categorized into pre- and 
post-menopausal groups for analyses in Table 4. 
The significant positive correlations between serum 
Ca++-C and all four lipid markers remained in both 
pre- and post-menopausal women groups.
Table 5 shows the results of levels of serum 
lipids in female and male subjects according to the 
concentrations of serum Ca++-C. In women, those 
in the low serum Ca++-C group had the lowest 
fasting total cholesterol, HDL-c and LDL-c levels, 
those in the medium serum Ca++-C group had an 
intermediate total cholesterol, HDL-c and LDL-c 
levels, and those in the high calcium group had the 
highest total cholesterol, TG, HDL-c and LDL-c 
levels, (P  0.0001 for all four variables). The only 
significant difference between calcium groups found 
in men was with HDL-c.
Moreover, the effects of 25-OH vitamin D 
and PTH were adjusted in a selected group 
of  100 women (Table 6). Subjects with low serum 
Ca++-C concentrations had a significantly lower level 
of fasting total cholesterol, TG and LDL-c compared 
Table 1. Physical characteristics and biochemical measurements of subjects.
 Females (n = 1383–1472) Males (n = 422–435)
Age (years) 44.7 ± 11.3 (19–84) 41.0 ± 13.3 (19–82)
Weight (kg) 69.6 ± 14.1 (39.5–156.8) 85.0 ± 14.2 (53.6–149.4)
height (cm) 162.1 ± 5.8 (135.0–186.7) 175.7 ± 6.3 (157–198)
BMi (kg/m2) 26.5 ± 5.3 (16.0–54.3) 27.6 ± 4.4 (16.8–50.4)
Waist circumference (cm) 90.9 ± 14.4 (54–168) 97.9 ± 11.9 (64–149)
% FAT 37.8 ± 7.5 (4.6–60.2) 25.3 ± 7.5 (5.6–48.0)
% FAT-Trunk 38.9 ± 8.8 (3.9–65.3) 30.0 ± 8.8 (4.7–53.0)
Lean body mass (kg) 39.7 ± 5.5 (25.8–81.9) 59.5 ± 7.5 (37.2–100.5)
serum Ca++ (mmol/L) 2.34 ± 0.12 (1.72–3.01) 2.36 ± 0.12 (1.76–2.81)
serum Ca++-C (mmol/L)*1,*2 2.33 ± 0.11 (1.67–2.92) 2.32 ± 0.10 (1.91–2.68)
serum Phosphorus (mmol/L) 1.21 ± 0.17 (0.69–1.97) 1.13 ± 0.18 (0.65–1.66)
serum Mg++ (mmol/L)*1 0.88 ± 0.08 (0.47–1.48) 0.89 ± 0.11 (0.11–1.85)
Cholesterol (mmol/L) 5.21 ± 1.03 (2.40–9.98) 5.02 ± 0.97 (2.82–6.97)
Triglyceride (mmol/L) 1.15 ± 0.70 (0.23–5.88) 1.24 ± 0.71 (0.35–3.75)
hDL-cholesterol (mmol/L) 1.56 ± 0.38 (0.77–3.25) 1.40 ± 0.36 (0.65–2.34)
LDL-cholesterol (mmol/L)*1 3.12 ± 0.89 (0.65–7.61) 3.06 ± 0.84 (1.31–5.00)
risk factor 3.48 ± 0.95 (0.68–8.41) 4.22 ± 1.16 (2.08–8.51)
Data are means ± sD; *1p value  0.05–0.001 for all variables, except for serum Ca++-C, Mg++ and LDL-cholesterol, in the comparison between women 
and men using student’s t-test; *2Calcium-C means total serum calcium corrected by albumin (Ca + 0.1 × (40-albumin)/6).
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with subjects with high calcium concentration 
(P  0.0001, = 0.015 and = 0.004, respectively).
Discussion
The regulation of serum calcium and the metabolism 
of lipids involve many hormonal and physiological 
factors. Factors such as age, gender, physical 
activity level, and body composition are contributors 
to the variations of major lipids in the general 
population.34,35 Consequently, when attempting to 
reveal true associations between total serum calcium 
and any variable of lipids, it is critical to exclude 
or control as many confounding factors as possible. 
Age is usually a constant non-modifiable risk factor 
for dyslipidemia.36,37 Total serum cholesterol, LDL-c 
and TG levels increase with age, while HDL-c levels 
decrease with age.37 In the present study, age was 
controlled in all analytical processes.
Gender is a constant factor that affects most 
physiological and pathophysiological conditions.38 
For example, liver is an important organ for 
lipid metabolism and significant sex differences 
in hepatic gene expression were seen in mice.39 
These differences contribute to sex differences in 
physiology, homeostasis, and steroid and foreign 
compound metabolism. Sex-related differences 
in gene expression are common across organisms 
including humans.40,41 Although most findings in 
our present study show similar results between 
men and women, sex difference in the relationship 
between serum calcium and TG are evident. The 
positive associations were strong in women in every 
aspect of the analyses. However, the relatively weak 
associations in men might be due in part to the small 
sample size compared with women.
During menopause there are physiological 
changes that occur and the metabolism in pre- and 
post menopausal women can be very different. This 
difference can be partly due to the significant change 
in female hormone levels and the increase of body 
fat. It is usually seen that menopause is associated 
with potentially adverse changes in lipids and 
lipoproteins.42 In this present study we found that 
the positive associations between serum Ca++ and 
abnormalities of lipids were stronger in pre- than in 
post- menopausal women.
The association between some lipids and serum 
calcium in humans was reported in a number of 
cross-sectional and longitudinal studies.15,24 These 
results were documented as part of a wide range 
of epidemiological studies targeting general risk 
factors. De Bacquer and colleagues was the first 
group to specifically design a study to investigate 
the link of serum calcium with total cholesterol and 
HDL-c.43 Although age, sex and BMI were considered 
in the analyses, other potent confounding factors, 
with potentially important roles in influencing either 
serum calcium or lipid profiles including medication 
use, smoking, magnesium, percent body fat and 
menopausal status in women, were not studied.
There is a close association between dyslipidemia 
and obesity, especially central obesity.44 Central obesity 
is a major factor for dyslipidemia.38,45,46 Proper control 
and exclusion of the factors which influence obesity 
status would be critical to identifying the association 
between the two variables that we are interested in. 
A very recent study showed that dual-energy x-ray 
absorptiometry (DXA) derived abdominal-fat mass 
was the best predictor of blood lipid profiles.47 
Table 2. Partial correlations between serum Ca++-C 
concentration and lipids.
Females 
(n = 1373)
Males 
(n = 382)
parameter r p r p
Cholesterol (mmol/L) 0.26 0.0001 0.13 0.009
Triglyceride (mmol/L) 0.16 0.0001 0.05 ns
hDL (mmol/L) 0.11 0.0001 0.12 0.016
LDL (mmol/L) 0.19 0.0001 0.10 0.05
Confounding factors including age, trunk fat percentage, phosphorus and 
magnesium were correspondingly controlled in analyses where applicable.
Table 3. Partial correlations between serum Ca++-C 
concentration and lipids in subjects without taking any 
medication.
Females 
(n = 595)
Males 
(n = 236)
parameter r p r p
Cholesterol (mmol/L) 0.24 0.0001 0.19 0.004
Triglyceride (mmol/L) 0.09 0.028 0.12 0.056
hDL (mmol/L) 0.12 0.005 0.10 ns
LDL (mmol/L) 0.19 0.0001 0.16 0.015
Confounding factors including age, trunk fat percentage, phosphorus and 
magnesium were correspondingly controlled in analyses where applicable.
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The central fat percentage measured by DXA was 
controlled in all analyses in our study. Control of 
this variable strengthened our findings, leading to 
the conclusion that the associations of calcium status 
with lipids are independent of the influences of age, 
gender, menopausal status and body fat.
Sedentary life style in western countries is a 
risk factor for dyslipidemia.46,48 Physical activity is 
therefore a potent factor affecting circulating levels 
of lipids. The physical activity levels were taken 
into consideration in our data analyses as well. 
Importantly, the significant associations between 
serum calcium and lipids largely hold even after the 
control of physical activity levels.
The use of various medications including multi-
vitamin supplements was found in nearly 50% of the 
study participants. This is typical of adult subjects, 
including the young, middle aged, and elderly, 
recruited from the general population. Due to the 
diversity and different mixes of medications used it 
is difficult to classify subjects based on the types of 
pharmaceutical effect. Medication can affect serum 
Table 4. Partial correlations between serum Ca++-C concentration and lipids in pre- and post-menopausal women.
pre-menopausal 
(n = 763)
post-menopausal 
(n = 595)
parameter r p r p
Cholesterol (mmol/L) 0.31 0.0001 0.24 0.0001
Triglyceride (mmol/L) 0.16 0.0001 0.09 0.05
hDL (mmol/L) 0.17 0.0001 0.12 0.005
LDL (mmol/L) 0.21 0.0001 0.19 0.0001
Confounding factors including age, trunk fat percentage, phosphorus and magnesium were correspondingly controlled in analyses where applicable.
Table 5. Levels of serum cholesterol, Tg, hDL-c and LDL-c among low, medium and high serum Ca++-C groups.
calcium group Women Men
  n = 1378–1381 n = 386–389
Cholesterol (mmol/l) L 4.97 ± 0.88 5.01 ± 1.03
M 5.10 ± 1.02 5.11 ± 1.13
h 5.56 ± 1.09 5.17 ± 1.22
P value 0.0001* ns
Tg (mmol/L) L 1.03 ± 0.61 1.80 ± 0.91
M 1.07 ± 0.61 1.54 ± 1.08
h 1.32 ± 0.83 1.48 ± 1.11
P value 0.0001*1 ns
hDL-c (mmol/L) L 1.53 ± 0.35 1.20 ± 0.24
M 1.56 ± 0.37 1.22 ± 0.27
h 1.60 ± 0.41 1.28 ± 0.28
P value 0.017*2 0.05*2
LDL-c (mmol/L) L 2.96 ± 0.78 3.13 ± 0.88
M 3.06 ± 0.88 3.19 ± 0.95
h 3.36 ± 0.94 3.22 ± 0.94
P value  0.0001*1 ns
notes: Data are means ± SD. Significance assessed by one-way ANOVA, corrected by TUKEY method. *Significance between any two groups; 
*1Significance between L vs H, and M vs H; *2Significance between L vs H. 
Abbreviations: L, low calcium group; M, medium calcium group; h, high calcium group.
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lipids through many mechanisms. Endogenous 
synthesis of cholesterol in the liver is controlled through 
modification of microsomal enzyme 3-hydroxy-
3-methylglutaryl- CoA (HMG-CoA) reductase 
activity, the rate limiting step. Medications targeting 
HMG-CoA reductase such as statins can effectively 
lower cholesterol levels and is widely used in patients 
with dyslipidemia.49 Other medications including 
fibric acids and nicotinic acid also have powerful 
lipid lowering effects and are widely used in patients 
with metabolic syndrome and type 2 DM.50 Other 
drugs that are not primarily targeting lipids may 
change lipids as well. Moreover oral contraceptives 
are commonly used in women of reproductive age. 
Oral contraceptives can cause hypertriglyceridemia 
in some women.51 It is essential to exclude both the 
primary and the secondary influence of all types 
of medication on the variation of serum lipids. 
Analyses according to medication status were 
therefore performed. Equally significant associations 
were observed in non-medication users although 
the number of subjects was reduced by about half 
compared to the total group. This may indicate that 
the positive association between serum calcium and 
lipid profile becomes clearer when not confounded 
by the influence of medications.
Serum calcium levels are regulated by the action 
of PTH. PTH acts to increase the concentration 
of calcium in the blood.52 PTH regulates serum 
calcium levels through its effects on bone, kidney 
and intestines. Moreover, PTH increases the activity 
of 1-α-hydroxylase enzyme, which converts 25-
hydroxycholecalciferol to 1, 25-dihydroxycholecalciferol, 
the active form of vitamin D. Vitamin D regulates 
serum calcium levels by promoting calcium absorption 
from food in the intestines. Blood calcium status is 
also augmented by re-absorption of calcium in the 
kidneys as well. PTH and vitamin D are the two 
hormones primarily involved in the regulation of 
serum calcium. The potential influence of these 
two hormones on the associations between serum 
calcium and lipids were excluded in the present study. 
Moreover the interactions between serum calcium, 
magnesium and phosphorus may potentially modify 
the concentration of  these cations. Hence the influence 
of magnesium and phosphorus was controlled in 
analyses in the present study. The positive correlation 
was simultaneously observed between Ca++ and 
good and bad cholesterols: LDL-c, TG and HDL-c. 
It seems confusing if we hypothesize that raised level 
of serum Ca++ is the molecular basis of high LDL-c 
and TG. Because this is an observational study, the 
nature of the study does not allow us to address this 
‘contradictory result’. This seemingly contradictive 
positive correlation with Ca++ could potentially be 
caused by numerous reasons. One of the explanations 
might be that our body tries to offset the rising LDL-c 
and TG by increasing the good cholesterol, HDL-c, 
simultaneously. Obviously this issue warrants further 
study in the future. To our knowledge, this is the 
first study designed to investigate the relationship 
between the variations of lipids and serum calcium 
in a large population with a comprehensive control 
of major confounding factors. Owing to the nature 
of association studies, positive associations like that 
described in the present study, can not establish a cause-
effect relationship. However, the carefully controlled 
study design and the strong association revealed in 
the analyses provide strong support for the need for 
downstream studies to examine if there is a molecular 
basis for the association between abnormalities 
of serum lipids and calcium variation.
In summary, the current study analyzed the 
relationship between the abnormalities of serum 
Table 6. Comparisons of lipids between low and high calcium groups adjusted for 25-Oh vitamin D and PTh.
Low calcium group  
(n = 50)
High calcium group  
(n = 50)
p
Cholesterol (mmol/L) 4.83 ± 0.12 5.83 ± 0.17 0.0001
Tg (mmol/L) 0.97 ± 0.08 1.40 ± 0.13 0.015
hDL-c (mmol/L) 1.54 ± 0.05 1.67 ± 0.06 ns
LDL-c (mmol/L) 2.85 ± 0.10 3.53 ± 0.15 0.004
student t-test. Values are shown in mean ± sE of raw values. Before analysis, total serum calcium was adjusted for 25-Oh vitamin D and PTh, serum 
cholesterol, Tg, hDL-c and LDL-c for age and %trunk fat using linear regression analysis.
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lipids and serum calcium. A positive association was 
found between serum Ca++-C and total cholesterol, 
TG, HDL-c and LDL-c in women from the general 
Newfoundland population. A similar trend was 
found in men. Demonstrating a relationship between 
calcium and serum lipids in spite of comprehensive 
control of major confounding factors makes this 
study unique and further strengthens the possibility 
of a direct relationship.
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